28478-46-8

Basic information

• Product Name: 4-HYDROXY-2-METHOXY-BENZOIC ACID METHYL ESTER
• Synonyms: Methyl 4-hydroxy-2-methoxybenzoate;Methyl 4-hydroxy-o-anisate
• CAS NO: 28478-46-8
• Molecular Formula: C₉H₁₀O₄
• Molecular Weight: 182.17
• Mol File: 28478-46-8.mol
• Article Data: 17

Chemical Properties

• Melting Point: 150-151℃
• Boiling Point: 326.942°C at 760 mmHg
• Flash Point: 132.419°C
• Appearance: /
• Density: 1.216g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 4-HYDROXY-2-METHOXY-BENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXY-2-METHOXY-BENZOIC ACID METHYL ESTER(28478-46-8)
• EPA Substance Registry System: 4-HYDROXY-2-METHOXY-BENZOIC ACID METHYL ESTER(28478-46-8)

Safety Data

• Hazardous Substances Data: 28478-46-8(Hazardous Substances Data)

Usage

Description

4-HYDROXY-2-METHOXY-BENZOIC ACID METHYL ESTER, also known as Methyl 4-Hydroxy-2-Methoxybenzoate, is an organic compound with the molecular formula C9H10O5. It is a methyl ester derivative of hydroxymethoxybenzoic acid and is characterized by its aromatic structure and functional groups. 4-HYDROXY-2-METHOXY-BENZOIC ACID METHYL ESTER is known for its potential applications in various industries, particularly in the pharmaceutical sector.

Uses

Used in Pharmaceutical Industry:
4-HYDROXY-2-METHOXY-BENZOIC ACID METHYL ESTER is used as a reagent for the synthesis of Ceralifimod, a sphingosine-1-phosphate receptor agonist. Ceralifimod is utilized in the treatment of autoimmune diseases, as it modulates the immune system and helps in managing the symptoms and progression of these conditions.

InChI:InChI=1/C9H10O4/c1-12-8-5-6(10)3-4-7(8)9(11)13-2/h3-5,10H,1-2H3

Upstream product

• 61539-61-5 1,1-dimethoxy-3-trimethylsilyloxy-1,3-butadiene 
• 922-67-8 propynoic acid methyl ester 
• 28478-45-7 methyl 4-benzyloxy-2-methoxybenzoate 
• 89-86-1 4-hydroxysalicylic acid 
• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 102127-34-4 4-bromo-3-methoxyphenol 
• 90111-34-5 4-hydroxy-2-methoxybenzoic acid 
• 18278-34-7 4-hydroxy-2-methoxybenzaldehyde 
• 124-41-4 sodium methylate 
• 136669-90-4 methyl 2-hydroxy-4-(trityloxy)benzoate 
• 5427-29-2 methyl 2-hydroxy-4-benzyloxybenzoate 
• 2150-47-2 methyl 2,4-dihydroxybenzoate 
• 845307-11-1 methyl 2-hydroxy-4-pivaloyloxybenzoate 

Downstream Products

• 62443-16-7 2-Methoxy-4-tetradecyloxy-benzoic acid methyl ester 
• 181269-73-8 methyl 5-fluoro-4-hydroxy-2-methoxybenzoate 
• 194152-21-1 5-Fluoro-2-methoxy-4-((R)-1-pyridin-4-yl-ethoxy)-benzoic acid methyl ester 
• 194152-23-3 5-Fluoro-2-methoxy-4-((R)-1-pyridin-4-yl-ethoxy)-benzoic acid 
• 162044-60-2 1-[1-(4-Hydroxy-2-methoxy-benzoyl)-piperidin-4-yl]-1,4-dihydro-benzo[d][1,3]oxazin-2-one 
• 194151-34-3 (+/-)-1-{1-[4-(1-{piperidin-4-yl}ethoxy)-2-methoxybenzoyl]-piperidin-4-yl}-4H-3,1-benzoxazin-2(1H)-one 
• 194151-64-9 (R)-1-{1-[4-(1-{pyridin-4-yl}ethoxy)-5-fluoro-2-methoxybenzoyl]-piperidin-4-yl}-4H-3,1-benzoxazin-2(1H)-one 
• 1229688-83-8 methyl 4-(cis-2-phenyl-1-cyclohexanoyloxy)-2-methoxybenzoate 
• 194151-75-2 methyl 4-(4-tetra-hydropyranoyloxy)-2-methoxy-benzoate 

Relevant articles and documents

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR

This disclosure pertains to compounds, the preparation thereof, and the use of these compounds in the treatment of prostate cancer, including metastatic and/or castrate-resistant prostate cancer, in subjects in need thereof.

Imidazole-containing condensed tricyclic compound and application thereof

The invention discloses an imidazole-containing condensed tricyclic compound adopting the structure as shown in the formula (I) or pharmaceutically acceptable salts, stereisomers or prodrug molecules thereof. The imidazole-containing condensed tricyclic compound has the IDO1 activity regulation function, can enhance T-cell activation through blocking immune checkpoints IDO1, is used for treating IDO1-mediated immunosuppression, and therefore, can become an effective medicine for treating malignant tumors. When used together with checkpoint protein anti-body drugs or other anti-cancer drugs, the imidazole-containing condensed tricyclic compound can enhance the anti-cancer effect. Meanwhile, the imidazole-containing condensed tricyclic compound has the potential of effectively treating IDO1 abnormity related immunosuppressive diseases and has a high application value.

PHARMACEUTICAL COMPOUNDS

This invention relates to compounds that inhibit or modulate the activity of Chk-1 kinase. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds.